These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 20650436)

  • 1. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
    Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD
    JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group.
    Brodie BR; Wilson H; Stuckey T; Nussbaum M; Laurent S; Bradshaw B; Humphrey A; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Simonton CA;
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1105-12. PubMed ID: 19926052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial.
    Brilakis ES; Lichtenwalter C; Abdel-karim AR; de Lemos JA; Obel O; Addo T; Roesle M; Haagen D; Rangan BV; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S
    JACC Cardiovasc Interv; 2011 Feb; 4(2):176-82. PubMed ID: 21349456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial.
    Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Holper EM; Haagen D; Saeed B; Iturbe JM; Shunk K; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S; Brilakis ES
    JACC Cardiovasc Interv; 2009 Sep; 2(9):855-60. PubMed ID: 19778774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: results from the Prairie "Real World" Stent Registry.
    Goswami NJ; Gaffigan M; Berrio G; Plessa AL; Pfeiffer AM; Markwell SJ; Mishkel GJ
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):93-100. PubMed ID: 19787803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of chronic renal insufficiency on clinical outcomes in patients undergoing saphenous vein graft intervention with drug-eluting stents: a multicenter Southern Californian Registry.
    Lee MS; Hu PP; Aragon J; Shah A; Bhatia R; Jones N; Penny W; French W; Tobis J; Mahmud E
    Catheter Cardiovasc Interv; 2010 Aug; 76(2):272-8. PubMed ID: 20623716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome after saphenous vein stenting with Taxus Liberté stent: results from the OLYMPIA Registry (TAXUS Liberté Postapproval Global Program).
    Mendiz OA; Ahmed WH; Fava CM; vom Dahl J; Valdivieso LR; Lev GA; R Thomas M;
    Angiology; 2012 Nov; 63(8):574-8. PubMed ID: 22238352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seven-year safety and efficacy of the unrestricted use of drug-eluting stents in saphenous vein bypass grafts.
    Nauta ST; Van Mieghem NM; Magro M; Deckers JW; Simsek C; Van Geuns RJ; Van Der Giessen WJ; De Jaegere P; Regar E; Van Domburg RT; Serruys PW
    Catheter Cardiovasc Interv; 2012 May; 79(6):912-8. PubMed ID: 21542111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of sirolimus-eluting stents with paclitaxel-eluting stents in saphenous vein graft intervention (from a multicenter Southern California Registry).
    Lee MS; Hu PP; Aragon J; Shah AP; Oyama J; Dhoot J; Iqbal Z; Jones N; Penny W; Tobis J; Mahmud E; French W
    Am J Cardiol; 2010 Aug; 106(3):337-41. PubMed ID: 20643242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.
    Tolerico PH; Cohen DJ; Kleiman NS; Berger PB; Brilakis ES; Piana RN; Shammo S; Keyes MJ; Kennedy KF; Massaro JM; Saucedo JF;
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1127-36. PubMed ID: 22431166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry.
    Brilakis ES; Wang TY; Rao SV; Banerjee S; Goldman S; Shunk K; Kar B; Holmes DR; Dai D; Chin CT; Harding TM; Roe MT
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1068-73. PubMed ID: 20965466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of patients with acute myocardial infarction from a saphenous vein graft culprit undergoing percutaneous coronary intervention.
    Gaglia MA; Torguson R; Xue Z; Gonzalez MA; Ben-Dor I; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2011 Jul; 78(1):23-9. PubMed ID: 21061247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and effectiveness of drug-eluting stents for the treatment of saphenous vein grafts disease: a population-based study.
    Ko DT; Guo H; Wijeysundera HC; Zia MI; Džavík V; Chu MW; Fremes SE; Cohen EA; Tu JV
    JACC Cardiovasc Interv; 2011 Sep; 4(9):965-73. PubMed ID: 21939936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial.
    Stone GW; Goldberg S; O'Shaughnessy C; Midei M; Siegel RM; Cristea E; Dangas G; Lansky AJ; Mehran R
    JACC Cardiovasc Interv; 2011 Mar; 4(3):300-9. PubMed ID: 21435608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions.
    Wöhrle J; Nusser T; Kestler HA; Kochs M; Hombach V
    Clin Res Cardiol; 2007 Feb; 96(2):70-6. PubMed ID: 17146605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year clinical outcomes of paclitaxel-eluting stents for in-stent restenosis in patients from the ARRIVE programme.
    Lee MS; Yang T; Lasala JM; Cox DA; Bowman TS; Starzyk RM; Dawkins KD
    EuroIntervention; 2011 Jul; 7(3):314-22. PubMed ID: 21729833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
    Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.